Terol M J, Cid M C, López-Guillermo A, Juan M, Yagüe J, Miralles A, Vilella R, Vives J, Cardesa A, Montserrat E, Campo E
Postgraduate School of Hematology Farreras Valent, University of Barcelona, Spain.
Tissue Antigens. 1996 Oct;48(4 Pt 1):271-7. doi: 10.1111/j.1399-0039.1996.tb02645.x.
ICAM-3/CD50 is a recently described LFA-1 counter receptor that seems to play an important role in the initiation of immune responses. In this study we have examined the expression of ICAM-3/CD50 in a large series of human neoplasms including 101 Non-Hodgkin's lymphomas (NHL), 26 Hodgkin's disease, and 38 solid tumors to define the distribution patterns of this molecule in malignant neoplasms and their possible correlation with clinical and pathological characteristics of the patients. In NHL, ICAM-3/CD50 was expressed in almost all the tumors with a tendency to be lost in high grade lymphomas. Reed-Sternberg cells and their variants in Hodgkin's disease were always negative independently of the histological subtype of the disease. No expression was observed in tumor epithelial cells of the 38 solid tumors examined. Strong endothelial cell staining was observed in 31% of the NHL and 31% of Hodgkin's disease. ICAM-3 expression in these cases was restricted to small tumor vessels. ICAM-3 expression in endothelial cells of NHL was significantly more frequent in high grade (40%) than in low grade lymphomas (14%) (p = 0.012). In addition, tumor vessels were also positive in 29% of solid tumors independently of the histological type. No correlation was observed between ICAM-3 expression in tumor or endothelial cells and other clinical and pathological characteristics of the patients. These findings indicate that ICAM-3 expression in human tumors is restricted to hematological neoplasms with a tendency to be lost in high grade lymphomas and Hodgkin's disease. ICAM-3 is also expressed by endothelial cells from tumor-associated neovascularization in both lymphoid and solid tumors.
细胞间黏附分子-3/CD50是最近发现的淋巴细胞功能相关抗原-1（LFA-1）的反受体，似乎在免疫反应的启动中起重要作用。在本研究中，我们检测了一系列人类肿瘤中细胞间黏附分子-3/CD50的表达情况，这些肿瘤包括101例非霍奇金淋巴瘤（NHL）、26例霍奇金病和38例实体瘤，以确定该分子在恶性肿瘤中的分布模式及其与患者临床和病理特征的可能相关性。在NHL中，几乎所有肿瘤都表达细胞间黏附分子-3/CD50，在高级别淋巴瘤中有丢失的趋势。霍奇金病中的里德-斯腾伯格细胞及其变异型无论疾病的组织学亚型如何均始终为阴性。在所检测的38例实体瘤的肿瘤上皮细胞中未观察到表达。在31%的NHL和31%的霍奇金病中观察到内皮细胞强染色。这些病例中的细胞间黏附分子-3表达仅限于小肿瘤血管。NHL内皮细胞中细胞间黏附分子-3的表达在高级别淋巴瘤（40%）中比在低级别淋巴瘤（14%）中显著更常见（p = 0.012）。此外，29%的实体瘤中肿瘤血管也呈阳性，与组织学类型无关。未观察到肿瘤或内皮细胞中细胞间黏附分子-3的表达与患者的其他临床和病理特征之间存在相关性。这些发现表明，人类肿瘤中细胞间黏附分子-3的表达仅限于血液系统肿瘤，在高级别淋巴瘤和霍奇金病中有丢失的趋势。细胞间黏附分子-3在淋巴瘤和实体瘤中与肿瘤相关新生血管的内皮细胞中也有表达。
